Sg Americas Securities, LLC Aeglea Bio Therapeutics, Inc. Transaction History

Sg Americas Securities, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 29, 2022	BUY	$0.5 - $2.66 $8,911 - $47,406	17,822 New	17,822 $9,000
Q1 2022 Apr 29, 2022	SELL	$1.87 - $4.77 $20,631 - $52,627	-11,033 Closed	0 $0
Q4 2021 Feb 07, 2022	SELL	$3.5 - $8.42 $61,407 - $147,728	-17,545 Reduced 61.39%	11,033 $52,000
Q3 2021 Nov 01, 2021	BUY	$6.03 - $7.95 $172,325 - $227,195	28,578 New	28,578 $227,000
Q3 2020 Nov 09, 2020	SELL	$6.51 - $9.33 $149,020 - $213,573	-22,891 Closed	0 $0
Q2 2020 Jul 20, 2020	BUY	$4.01 - $11.04 $49,992 - $137,635	12,467 Added 119.6%	22,891 $212,000
Q1 2020 Apr 30, 2020	BUY	$3.51 - $8.48 $36,588 - $88,395	10,424 New	10,424 $49,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg Americas Securities, LLC with notifications on news.